Progressive augmentation and ventilatory long-term facilitation are enhanced in sleep apnoea patients and are mitigated by antioxidant administration.
Progressive augmentation (PA) and ventilatory long-term facilitation (vLTF) of respiratory motor output are forms of respiratory plasticity that are initiated during exposure to intermittent hypoxia. The present study was designed to determine whether PA and vLTF are enhanced in obstructive sleep apnoea (OSA) participants compared to matched healthy controls. The study was also designed to determine whether administration of an antioxidant cocktail mitigates PA and vLTF. Thirteen participants with sleep apnoea and 13 controls completed two trials. During both trials participants were exposed to intermittent hypoxia which included twelve 4-min episodes of hypoxia (P(ETCO(2)), 50 mmHg; P(ETCO(2)), 4 mmHg above baseline) followed by 30 min of recovery. Prior to exposure to intermittent hypoxia, participants were administered, in a randomized fashion, either an antioxidant or a placebo cocktail. Baseline measures of minute ventilation during the placebo and antioxidant trials were not different between or within groups. During the placebo trial, PA was evident in both groups; however it was enhanced in the OSA group compared to control (last hypoxic episode 36.9 +/- 2.8 vs. 27.7 +/- 2.2 l min(-1); P <or= 0.01). Likewise, vLTF was evident during the recovery period in both groups; on the other hand vLTF was greater in the OSA group compared to control (29.3 +/- 2.8 vs. 20.4 +/- 1.3 l min(-1); P <or= 0.01). PA and vLTF were reduced in the OSA group following antioxidant administration compared to the placebo (PA 30.6 +/- 2.0 vs. 36.9 +/- 2.8 l min(-1), P <or= 0.01; vLTF 23.3 +/- 1.4 vs. 29.3 +/- 2.8 l min(-1), P <or= 0.05). We conclude that PA and vLTF are enhanced in participants with OSA and that these forms of respiratory plasticity are mitigated after treatment with an antioxidant cocktail.
Lee
Dorothy S
DS
John D. Dingell Veterans Administration Medical Center, Wayne State University, Detroit, MI 48201, USA.
Badr
M Safwan
MS
Mateika
Jason H
JH
D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage*; D006801:Humans; D000860:Hypoxia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D017286:Polysomnography / Q000379:methods; D012123:Pulmonary Ventilation / Q000187:drug effects* / Q000502:physiology*; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D013482:Superoxide Dismutase / Q000008:administration & dosage; D013997:Time Factors; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives; D014810:Vitamin E / Q000008:administration & dosage
D000975:Antioxidants; D014451:Ubiquinone; D014810:Vitamin E; D013482:Superoxide Dismutase; C024989:coenzyme Q10